

## Division of Hematology/Oncology Developmental Therapeutics Program Rounds

**Date:** Wednesday, January 18<sup>th</sup>, 2017

**Time:** 12:00pm – 1:00pm (Lunch will be provided)

**Location:** McGaw Pavilion Daniel Hale Williams Auditorium (2<sup>nd</sup> floor)

**“The failure of immunotherapy for brain cancer:  
Challenging dogma to improve success”**



### **Derek Wainwright, PhD**

*Assistant Professor of Neurological Surgery,  
Medicine (Hematology/Oncology) and  
Microbiology-Immunology*

**At the conclusion of this activity, participants should be able to:**

- 1: Evaluate recent results of Phase I, II and III clinical trial data for immunotherapy of glioblastoma patients.**
- 2: Understand preclinical studies that led to immunotherapy-based clinical trials for glioblastoma patients.**
- 3. Consider emerging data demonstrating distinct differences in immunotherapeutic efficacy of glioblastoma, versus other types of cancer.**

**Disclosure information:** Dr. Wainwright has nothing to disclose. The course director, Dr. Francis Giles, and planning committee members of this activity, Drs. Kaplan, Kalyan, Carneiro, Kumthekar, and Chae, as well as Anne McDowell and Emily Levy, have nothing to disclose.

**FSM's CME Leadership and Staff listed have nothing to disclose:** John X. Thomas, Jr., PhD, Sr. Associate Dean for Medical Education, Clara Schroedl, Medical Director of CME, Sheryl Corey, CME Manager, Jennifer Banys & Michelle Mallery Puposar, CME Project Specialists.

The Northwestern University Feinberg School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Northwestern University Feinberg School of Medicine designates this live activity for a maximum of **(1) AMA PRA Category 1 Credit(s)**<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.